ARTICLE | Company News
Agendia acquires TUO-gene expression profile
February 2, 2005 8:00 AM UTC
Agendia (Amsterdam, the Netherlands) acquired from Arcturus (Mountain View, Calif.) exclusive European rights to the TUO (tumor of unknown origin) gene expression profile. Agendia uses the profile in ...